Global Novel Vaccine Delivery Devices Industry Report 2019-2030
DUBLIN, Jan. 3, 2020 /PRNewswire/ -- The "Novel Vaccine Delivery Devices Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Novel Vaccine Delivery Devices Market, 2019-2030
features an extensive study of the current landscape and the likely future opportunities associated with novel vaccine delivery devices, over the next 10-12 years.
One of the key objectives of the report was to estimate the existing market size and assess potential future growth opportunities for novel vaccine delivery devices. Based on various parameters, such as number of marketed / pipeline products, price of devices (for commercially available products only) and estimated annual adoption rate, we have developed an informed estimate on the likely evolution of the market over the period 2019-2030.
In addition, we have provided the likely distribution of the current and forecasted opportunities across:
-- [A] type of device (electroporation-based needle free injection systems,
oral delivery systems, nasal delivery systems, jet injectors,
microneedle patches and microinjectors)
-- [B] route of administration (oral, intramuscular, intranasal,
intradermal and subcutaneous)
-- [C] type of vaccine (Bivalent Oral Polio Vaccine, BCG Vaccine,
DTP-HepB-Hib Vaccine, Pneumococcal Conjugate Vaccine, Influenza Vaccine,
Measles Vaccine, Tetanus-Diphtheria Vaccine and Others)
-- [D] key geographical regions (North America, Europe, Asia and rest of
the world)
According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025.
Recent global immunization records indicate that more than 115 million children were immunized against diphtheria, tetanus and pertussis in 2018. Given the rate at which the global population is growing, the demand for vaccines is likely to increase significantly.
However, biopharmaceutical developers are plagued by concerns related to storage and handling of such preventive / therapeutic products. One commonly reported issue is related to vaccine administration. Despite the success of conventional delivery approaches, which rely on the intramuscular and subcutaneous routes of administration, the present scenario dictates that further improvements are required in order to deal with challenges related to large scale immunization initiatives. Some of the commonly reported disadvantages of the conventional (parenteral) mode of delivery include pain during administration, risk of cross contamination, needlestick injuries, and inaccurate dosing.
Of late, there has been an evident shift in interest to non-invasive immunization methods, which include oral, intranasal and transdermal modes of administration. Currently, many biopharmaceutical companies and clinical research institutes are engaged in the development of novel vaccine delivery systems, taking into consideration the specific requirements of large scale immunization initiatives. As a result, significant efforts have been put into the development of drug delivery technologies / devices, such as microneedle patches, electroporation-based needle free injection systems, jet injectors, inhalation-based delivery systems, biodegradable implants and certain novel types of oral delivery systems.
It is worth highlighting that most of the aforementioned systems are specifically being designed to facilitate pain-free administration of vaccines and allow self-administration. Vaccine developers are also attempting to devise ways to make such products more stable so as to eliminate the need for cold chain in transporting such products. Given the pace of innovation in this field, it is anticipated that the novel vaccine delivery devices market is likely to witness radical changes in the coming years.
Amongst other elements, the report includes:
-- A detailed assessment of the overall novel vaccine delivery devices
market landscape, featuring an elaborate list of device developers and
analysis based on a number of relevant parameters, such as year of
establishment, company size, geographical location, type of device
(autoinjectors, microneedle patches, jet injectors, dry powder inhalers,
microinjectors, nasal delivery systems, pen injectors, biodegradable
implants, electroporation-based needle free injection systems and novel
oral delivery systems), route of administration (subcutaneous,
transdermal, intramuscular, intradermal, inhalation, intranasal, and
oral), drug delivery mechanism (mechanical, electrical and
miscellaneous), nature of vaccine administration (invasive and
non-invasive), speed of administration (fast, moderate and slow), self-
administration potential, provisions for audio / visual feedback, device
usability (disposable and reusable), type of needle (needleless, fixed
needle, detachable needle, and hidden needle), and current development
status of novel vaccine delivery systems (preclinical / discovery,
clinical and marketed).
-- A detailed competitiveness analysis of novel vaccine delivery devices,
taking into consideration the supplier power (based on the year of
establishment of developer company) and key product specifications (such
as route of administration, device usability, drug delivery mechanism,
availability of needle safety system, speed of administration,
self-administration potential, provisions for audio / visual feedback,
nature of administration, cold chain requirement and current status of
development).
-- An analysis evaluating the effectiveness of various vaccines delivery
devices in order to compare their respective strengths and capabilities
based on a variety of relevant parameters, such as type of active
ingredient, dosage form, route of administration, target disease
indication and target patient population.
-- A detailed list of marketed and pipeline vaccine candidates that are
anticipated to be developed in combination with novel vaccine delivery
devices in the near future, featuring analysis based on parameters, such
as type of active ingredient, dosage form, route of administration,
target disease indication and target patient population.
-- Elaborate profiles of prominent product developers engaged in this
domain; each profile features a brief overview of the company, its
financial information (if available), information on its product
portfolio, recent developments and an informed future outlook.
-- An analysis of recent collaborations and partnership agreements inked in
this domain since 2014, including details of deals that were / are
focused on novel vaccine delivery devices. The partnerships captured in
the report were analyzed on the basis of year of establishment, type of
agreement, type of device, type of vaccine, type of active ingredient
and target disease indication.
-- A discussion on important, industry-specific trends, key market drivers
and challenges, under a comprehensive SWOT framework, featuring a
qualitative Harvey ball analysis that highlights the relative impact of
each SWOT parameter on the overall market.
In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry.
The report features detailed transcripts of interviews held with the following industry stakeholders:
-- Michael Schrader, Chief Executive Officer and Founder, Vaxess
Technologies
-- Mikael Ekstrom and Roger Lassing, Vice President, Business Development,
Iconovo
-- Henry King, Market Intelligence and Business Development Manager,
Innoture
Key Topics Covered
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Vaccines
3.2.1. Classification of Vaccines
3.2.2. Key Components of a Vaccine Formulation
3.2.3. Expression Systems Used for Vaccine Production
3.3. Vaccine Delivery
3.3.1. Intradermal Route
3.3.2. Subcutaneous Route
3.3.3. Intramuscular Route
3.3.4. Oral Route
3.3.5. Intranasal Route
3.3.6. Inhalation Route
3.4. Key Challenges Associated with Vaccine Delivery
3.5. Novel Approaches for Vaccine Delivery
3.5.1. Autoinjectors
3.5.2. Biodegradable Implants
3.5.3. Buccal / Sublingual Vaccine Delivery Systems
3.5.4. Electroporation-based Needle Free Injection Systems
3.5.5. Inhalation / Pulmonary Vaccine Delivery Systems
3.5.6. Jet Injectors
3.5.7. Microinjection System
3.5.8. Novel Orally Administrable Formulations
3.6. Future Perspectives
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Marketed Vaccines Landscape
4.3. Clinical-Stage Vaccines Landscape
4.4. Novel Vaccine Delivery Devices: Overall Market Landscape
4.4.1. Analysis by Type of Device
4.4.2. Analysis by Route of Administration
4.4.3. Analysis by Drug Delivery Mechanism
4.4.4. Analysis by Nature of Vaccine Administration
4.4.5. Analysis by Speed of Vaccine Administration
4.4.6. Analysis by Self-Administration Potential
4.4.7. Analysis by Availability of Audio / Visual Feedback
4.4.8. Analysis by Device Usability
4.4.9. Analysis by Type of Needle
4.4.10. Analysis by Stage of Development
4.5. Novel Vaccine Delivery Device Developers: Overall Market Landscape
4.5.1. Analysis by Type of Developer
4.5.2. Analysis by Year of Establishment
4.5.3. Analysis by Company Size
4.54. Analysis by Geographical Location
5. DEVICE COMPETITIVENESS ANALYSIS
5.1. Chapter overview
5.2. Assumptions and Methodology
5.3. Novel Vaccine Delivery Devices: Competitive Landscape
5.4. Concluding Remarks
6. TECHNOLOGY EFFECTIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Vaccine Delivery Devices: Technology Effectiveness Analysis
6.4.1. Devices for Marketed Vaccines
6.4.2. Devices for Clinical-Stage Vaccines
7. NOVEL VACCINE DELIVERY DEVICES: LIKELY VACCINE CANDIDATES
7.1. Chapter Overview
7.2. Marketed Vaccines
7.2.1. Electroporation-based Needle Free Injection Systems: Likely Vaccine Candidates
7.2.2. Jet Injectors: Likely Vaccine Candidates
7.2.3. Microneedle Patches: Likely Vaccine Candidates
7.2.4. Nasal Delivery Systems: Likely Vaccine Candidates
7.2.5. Oral Delivery Systems for Liquid Formulations: Likely Vaccine Candidates
7.2.6. Oral Delivery Systems for Solid Formulations: Likely Vaccine Candidates
7.2.7. Prefilled Syringes: Likely Vaccine Candidates
7.3. Clinical-Stage Vaccines
7.3.1. Electroporation-based Needle Free Injection Systems: Likely Vaccine Candidates
7.3.2. Jet Injectors: Likely Vaccine Candidates
7.3.3. Microneedle Patches: Likely Vaccine Candidates
7.3.4. Nasal Delivery Systems: Likely Vaccine Candidates
7.3.5. Oral Delivery Systems for Liquid Formulations: Likely Vaccine Candidates
7.3.6. Oral Delivery Systems for Solid Formulations: Likely Vaccine Candidates
7.3.7. Prefilled Syringes: Likely Vaccine Candidates
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. 3M
8.3. Becton Dickinson
8.4. Consort Medical
8.5. D'Antonio Consultants International
8.6. Enesi Pharma
8.7. Ichor Medical
8.8. Iconovo
8.9. Inovio Pharmaceuticals
8.10. PharmaJet
8.11. Union Medico
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Novel Vaccine Delivery Devices: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Type of Device
9.3.4. Analysis by Type of Partnership and Type of Device
9.3.5. Analysis by Type of Vaccine and Type of Device
9.3.6. Analysis by Type of Active Ingredient
9.3.7. Analysis by Target Disease Indication
9.3.8. Popular Vaccine Delivery Devices: Analysis by Number of Partnerships
9.3.9. Most Active Industry Players: Analysis by Number of Partnerships
9.3.10. Geographical Analysis
10. SWOT ANALYSIS
10.1. Chapter Overview
10.2. Strengths
10.3. Weaknesses
10.4. Opportunities
10.5. Threats
10.6. Concluding Remarks
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Novel Vaccine Delivery Devices Market, 2019-2030
11.4. Global Novel Vaccine Delivery Devices Market: Distribution by Type of Device, 2019-2030
11.5. Global Novel Vaccine Delivery Devices Market: Distribution by Route of Administration, 2019-2030
11.6. Global Novel Vaccine Delivery Devices Market: Distribution by Type of Vaccine, 2019-2030
11.7. Global Novel Vaccine Delivery Devices Market: Distribution by Regions, 2019-2030
11.7.1. Novel Vaccine Delivery Devices Market in North America, 2019-2030
11.7.2. Novel Vaccine Delivery Devices Market in Europe, 2019-2030
11.7.3. Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030
11.7.4. Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030
12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. Vaxess Technologies
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Michael Schrader, Chief Executive Officer and Founder
12.3. Iconovo
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Mikael Ekstrom and Roger Lassing, Vice Presidents, Business Development
12.3. Innoture
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Henry King, Market Intelligence and Business Development Manager
13. CONCLUDING REMARKS
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
-- 3M
-- Abbott
-- AbCellera
-- ABO Pharmaceuticals
-- AC Immune
-- Accelovance
-- AdminMed
-- Aduro Biotech
-- Advagene Biopharma
-- Advaxis
-- Aelix Therapeutics
-- Aeras
-- Aesica Pharmaceuticals
-- Affinivax
-- Affiris
-- Agenus
-- AgResearch
-- Aimmune Therapeutics
-- Aivita Biomedical
-- AJ Vaccines
-- Aktiv-Dry
-- Alopexx Vaccine
-- AlphaVax
-- Altimmune
-- American Association for Cancer Research
-- Anhui Zhifei Longcom Biologic Pharmacy
-- Animal Health Board
-- Antares Pharma
-- Apogee Technology
-- Araclon Biotech
-- Archivel Farma
-- Argos Therapeutics
-- Astellas Pharma
-- AstraZeneca
-- Australian Respiratory and Sleep Medicine Institute
-- AVIR Green Hills Biotechnology
-- Axon Neuroscience
-- Barr Labs
-- Battelle
-- Bavarian Nordic
-- Baylor College of Medicine
-- BCN Peptides
-- Becton Dickinson
-- Beijing Center for Disease Control and Prevention
-- Beijing Institute of Biological Products
-- Beijing Minhai Biotechnology
-- Beijing Tricision Biotherapeutics
-- Beijing Wantai Biological Pharmacy Enterprise
-- Beijing Zhifei Lvzhu Biopharmaceutical
-- Bernhard Nocht Institute for Tropical Medicine
-- Bharat Biotech International
-- Bill and Melinda Gates Foundation
-- Bilthoven Biologicals
-- Biofabri
-- Bioject Medical Technologies
-- Biological E
-- Bio-Manguinhos
-- Biomedical Advanced Research and Development Authority
-- Biomedizinische Forschungs
-- BioNTech
-- BiondVax Pharmaceuticals
-- Bioneedle Technologies Group
-- Biontech
-- BioSerenTach
-- Birla Institute of Technology and Science
-- Boehringer Ingelheim
-- Boryung Pharmaceutical
-- BrightPath Biotherapeutics
-- Bristol-Myers Squibb
-- Bul Bio-National Center of Infectious and Parasitic Diseases
-- Cadila Health Care
-- Cancer Insight
-- Cancer Research UK
-- Cancer Vaccines Charitable Trust
-- CanSino Biologics
-- Capital Medical University
-- Celerion
-- Celgene
-- Celldex Therapeutics
-- Centers for Disease Control and Prevention
-- Center for Genetic Engineering and Biotechnology
-- Center for HIV/AIDS Vaccine Immunology (CHAVI)
-- Changhai Hospital
-- Charite University
-- Chengdu Institute of Biological Products
-- Children's Hospital of Philadelphia
-- Chinese PLA General Hospital
-- Chiron Behring Vaccines
-- Chumakov Federal Scientific Center for Research & Development of
Immune-And Biological Products
-- City of Hope Medical Center
-- College of Medicine and Allied Health Sciences
-- Consort Medical
-- Corium
-- CosMED Pharmaceutical
-- Cromos Pharma
-- CSL
-- CureVac
-- Curevo
-- DALI Medical Devices
-- Dana-Farber Cancer Institute
-- D'Antonio Consultants International
-- Dartmouth-Hitchcock Medical Center
-- Debiotech
-- Department of Health and Human Services
-- Duke University
-- Dutch Cancer Society
-- Dynavax Technologies
-- E Ink Holdings
-- E3D Elcam Drug Delivery Devices
-- Earle A. Chiles Research Institute
-- Elios Therapeutics
-- Emergent BioSolutions
-- Emergent Product Development
-- EMMES
-- Emory University
-- Enesi Pharma
-- EuBiologics
-- Federal State Budgetary Scientific Institution
-- FFF Enterprises
-- FHI 360
-- FIT Biotech
-- Flextronics International
-- Flinders University
-- FluGen
-- Forschungszentrum Jlich
-- Fourth Military Medical University
-- Fred Hutchinson Cancer Research Center
-- Fuda Cancer Hospital
-- FUJIFILM Pharmaceuticals
-- Gamaleya Research Institute of Epidemiology and Microbiology
-- GC Pharma
-- Genentech
-- GeneOne Life Science
-- Genetic Immunity
-- Genexine
-- Genocea Biosciences
-- Georgia Institute of Technology
-- GeoVax
-- German Cancer Research Center
-- Gilead Sciences
-- GlaxoSmithKline
-- GlobeImmune
-- GPO-MBP
-- Gradalis
-- Grameen Foundation
-- Green Cross
-- GreenSignal Bio Pharma
-- Gritstone Oncology
-- Guangdong 999 Brain Hospital
-- Guangzhou Anjie Biomedical Technology
-- Guangzhou Trinomab Biotech
-- Gynecologic Oncology Group
-- H. Lee Moffitt Cancer Center and Research Institute
-- Hadassah Medical Organization
-- Haffkine Bio Pharmaceutical
-- Hemispherx Biopharma
-- HIV Vaccine Trials Network
-- Hookipa Biotech
-- Hoosier Cancer Research Network
-- Hualan Biological Bacterin
-- Ichor Medical Systems
-- Iconovo
-- IDRI
-- Il-Yang Pharmaceutical
-- Immatics
-- Immune Biosolutions
-- Immune Design
-- Immunitor
-- ImmunoCellular Therapeutics
-- Immunomic Therapeutics
-- ImmuPatch
-- Imperial College London
-- Imugene
-- INCYTO
-- Infectious Disease Research Institute
-- Innoture Medical Technology
-- Inovio Pharmaceuticals
-- Inserm
-- Institut Pasteur
-- Institute of Clinical Research
-- Institute of Vaccines and Medical Biologicals
-- International Centre for Diarrheal Disease Research
-- International Vaccine Institute
-- Intravacc
-- Invectys
-- IPPOX Foundation
-- ISA Pharmaceuticals
-- Istari Oncology
-- Janssen Biotech
-- Japan BCG Laboratory
-- Jiangsu Jindike Biotechnology
-- Jiangsu Province Centers for Disease Control and Prevention
-- Jinan University Guangzhou
-- JN-International Medical
-- Johns Hopkins Bloomberg School of Public Health
-- Jonsson Comprehensive Cancer Center
-- Jurong Centers for Disease Control and Prevention
-- Kenya Medical Research Institute
-- Korean Center for Disease Control and Prevention
-- Kurve Technology
-- Laboratory Corporation of America
-- Leiden University Medical Center
-- Leidos
-- LG Chem
-- Likang Life Sciences
-- LimmaTech Biologics
-- London School of Hygiene and Tropical Medicine
-- Louisiana State University Health Sciences Center in New Orleans
-- LTS
-- Ludwig Institute for Cancer Research
-- Ludwig-Maximilians-University, Charite University
-- LuMind Research Down Syndrome Foundation
-- Madison Vaccines
-- Mahidol University
-- Marker Therapeutics
-- Massachusetts General Hospital
-- MassBiologics
-- Mayo Clinic
-- MCM Vaccine
-- McMaster University
-- MD Anderson Cancer Center
-- Medicago
-- Medical International Technologies
-- Medical Research Council
-- Medical University Innsbruck
-- Medical University of Vienna
-- Medigen Vaccine Biologics
-- MedImmune
-- MEDRx
-- MedsForAll
-- Memorial Sloan Kettering Cancer Center
-- Mercia Pharma
-- Merck
-- Microdermics
-- Micron Biomedical
-- Micropoint Technologies
-- MIKROGEN
-- Military Infectious Diseases Research Program
-- Minervax
-- Ministry of Health of the Russian Federation
-- Ministry of Health and Sanitation of Sierra Leone
-- Moffitt Clinical Research Network
-- Mogam Biotechnology Research Institute
-- Moore Medical
-- MSD Wellcome Trust Hilleman Laboratories
-- Mundipharma
-- Mylan
-- NanoPass Technologies
-- NantKwest
-- National Cancer Institute
-- National Institute for Health Research
-- National Institute for Medical Research
-- National Institute of Allergy and Infectious Diseases
-- National Institute of Biomedical Imaging and Bioengineering
-- National Institute on Aging
-- National Institutes of Health
-- National Pediatric Cancer Foundation
-- National University Hospital
-- Naval Medical Research Center
-- Nemaura Pharma
-- Nemera
-- Neon Therapeutics
-- Norwegian Institute of Public Health
-- Nova Immunotherapeutics
-- Nova Laboratories
-- Novartis
-- Novavax
-- NovInject
-- Nuance Designs
-- OncBioMune Pharmaceuticals
-- OncoPep
-- OncoTherapy Science
-- Oncovir
-- Olymvax Biopharmaceuticals
-- OptiNose
-- Organon Teknika
-- Osaka University
-- Ospedale San Raffaele
-- Oswaldo Cruz Foundation
-- Panacea
-- Parexel
-- PATH
-- PepTcell
-- Pfizer
-- PharmaJet
-- PHC Injection Device Technologies
-- Philipps University Marburg Medical Center
-- Philips Medisize
-- Picofluidics
-- Plumbline Life Sciences
-- Profectus BioSciences
-- Prometheon Pharma
-- PROSENEX Ambulatoriumbetriebs
-- Proswell Medical
-- Protein Sciences
-- Providence Cancer Center
-- Providence Health & Services
-- PT Bio Farma
-- Public Health England (PHE)
-- Queen's University Belfast
-- Research Foundation for Microbial Diseases of Osaka University
-- Rising Tide Foundation
-- Robbins Instruments
-- Robert Koch Institut
-- Romagnolo Scientific Institute for the Study and Treatment of Tumors
-- Roswell Park Cancer Institute
-- Royal Liverpool and Broadgreen University Hospitals NHS Trust
-- Russian Academy of Sciences
-- Sanaria
-- Sanofi
-- Scandinavian Biopharma
-- Sellas Life Sciences Group
-- Sementis
-- Seqirus
-- Serum Institute of India
-- Shanghai Bovax Biotechnology
-- Shanghai Houchao Biotechnology
-- Shantha Biotechnics
-- Shenzhen Geno-Immune Medical Institute
-- Shin Nippon Biomedical Laboratories
-- SHL Group
-- Sidney Kimmel Comprehensive Cancer Center
-- Sinovac Biotech
-- SK Bioscience
-- Skinject
-- Stand Up To Cancer
-- Stanford University
-- Statens Serum Institut
-- Stevanato Group
-- Swiss Group for Clinical Cancer Research
-- Takeda
-- Task Foundation
-- Teva Pharmaceutical
-- Texas Children's Hospital
-- The Aurum Institute
-- The Clatterbridge Cancer Center
-- The First Affiliated Hospital of Guangdong Pharmaceutical University
-- The Immunobiological Technology Institute
-- The Methodist Hospital System
-- The Wistar Institute
-- Themis Bioscience
-- TheraJect
-- Third Military Medical University
-- Transgene
-- Treos Bio
-- Trudell Medical International
-- TuBerculosis Vaccine Initiative
-- UbiVac
-- Union Medico
-- United States Agency for International Development
-- United States Army Medical Research Institute of Infectious Diseases
-- United States Department of Defense
-- University Health Network
-- University Hospital Tuebingen
-- University Medical Center Hamburg-Eppendorf
-- University Medical Center Groningen
-- University of Arkansas
-- University of California
-- University of Cape Town Lung Institute
-- University of Cologne
-- University of Copenhagen
-- University of Florida
-- University of Groningen
-- University of Iowa
-- University of Lausanne Hospitals
-- University of Liverpool
-- University of Maryland
-- University of Michigan
-- University of Oxford
-- University of Pennsylvania
-- University of Pisa
-- University of Pittsburgh
-- University of South Australia
-- University of Southampton
-- University of Sydney
-- University of Washington
-- University of Wisconsin
-- University of Zaragoza
-- US Army Medical Research and Material Command
-- Vaccibody
-- Vaccitech
-- Valeritas
-- Valneva
-- Vaxart
-- Vaxess Technologies
-- VAXIMM
-- Vaxine
-- Vaxxas
-- VBI Vaccines
-- Vetter Pharma
-- ViciniVax
-- ViroStatics
-- Walter Reed Army Institute of Research
-- Washington University School of Medicine
-- Weill Medical College of Cornell University
-- West Pharmaceuticals
-- World Health Organization
-- World Vision of Ireland
-- Wyeth Pharmaceuticals
-- XEME Biopharma
-- Xiamen Innovax Biotech
-- Xiamen University
-- Ypsomed
-- Zosano Pharma
For more information about this report visit https://www.researchandmarkets.com/r/vh9rj8
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-novel-vaccine-delivery-devices-industry-report-2019-2030-300980812.html
SOURCE Research and Markets
